- Infection and itching
- Irritation and burning
- Anti-inflammatory action
- Vaginal dryness

Medical Device CE

PJ PHARMA

Quality Assurance ISO 9001 - ISO 13485

MADE IN ITALY

MYCOTIC VULVOVAGINITIS

DESCRIPTION

Camogyn ovules are vaginal suppositores based on Hyluronic Acid, Lactic acid, Centella asiatica, Calendula officinalis, Chamomilla recutita, Melaleuca Alternifolia. It is indicated in all those conditions not of a pathological nature, affecting the vaginal mucosa, characterized by discomfort, ithching, irritation, burning and difficulty in sexual intercourse. Camogyn ovules performs a moisturizing, soothing and re-epithelializing action preventing and counteracting vaginal dryness.

DOSAGE

1 suppository/day inserted in the vagina at bedtime for 5-7 consecutive days (away from the menstrual period).

THERAPEUTIC INDICATIONS

- Vulvo irritation
- Flogistic and infective affections of vagina
- Vaginal dryness
- Recovery the normal vaginal flora and pH

PRESENTATION

Each pack of Camogyn ovules contains:
10 vaginal ovules of 2g in blister.

INGREDIENTS

Hyaluronic Acid Sodium Salt, Lactic Acid, Centella asiatica, Calendula officinalis, Chamomilla recutita, Melaleuca Alternifolia, 18-beta-glycyrrhetinic Acid, Phosphatidylcoline, Semisynthetic Triglycerides.

REGULATORY STATUS

- Class II
- Free sale certificate
- Declaration of conformity
- Certificate of origin (at the time of invoicing)
- ISO 13485 certificate

Camogyn

PLUS

VAGINAL DISCOMFORT: WHEN IT HAPPENES





Favours a natural process of **Cell Regeneration**

Film forming - **Protective features** Moisturizing

pH **Restore** Vaginal pH

HYALURONIC ACID:
- *Film-forming*
- *Moisturizing*
- *Lubricating Action*

Restore pH

LACTIC ACID
- Immediate Action

Vaginal environment

Protection

CENTELLA ASIATICA, CHAMOMILLA RECUTITA, CALENDULA OFFICINALIS:
- *Restoration of physiological conditions.*
- *Emollient and soothing action.*
- *Quick and prolonged relief.*

CLINICAL TEST

RISK ANALYSIS - according to UNI CEI EN ISO 14971
BIOCOMPATIBILITY – according to UNI EN ISO 10993-1:2010
- CYTOTOXICITY for DIRECT CONTACT - according to EN ISO 10993-5:1999 (UNI EN ISO 10993-5:2009)
- DELAYED HYPERENSIVITY TEST (GPMT) - according to EN ISO 10993-10:2002 (UNI EN ISO 10993-5:2010)

CLINICAL EVALUATION – according to MEDDEV 2.7-1 rev.4
STABILITY - according to ICH Guidelines and current F.U. and E.P.:
- LONG TERM

PJ PHARMA